BlackRock, Inc. Reduces Stake in Lexeo Therapeutics, Inc.

BlackRock, Inc. has filed a Schedule 13G/A amendment with the SEC, disclosing a reduction in its ownership of Lexeo Therapeutics, Inc. common stock. As of September 30, 2025, BlackRock owns 2,168,444 shares, representing a 4.0% ownership stake. This marks a significant decrease from its previous holdings, with a value change of -$22,437,676,421.16 and a shares change of -19,323,501. The filing indicates that BlackRock's ownership is now 4.0% of the total outstanding shares, down from a previous higher percentage. The filing also certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.